Cidara Therapeutics
CDTX
CDTX was delisted on the 6th of January, 2026.
27 hedge funds and large institutions have $35.6M invested in Cidara Therapeutics in 2024 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 9 increasing their positions, 0 reducing their positions, and 5 closing their positions.
111% more capital invested
Capital invested by funds: $16.9M → $35.6M (+$18.7M)
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
15.93% more ownership
Funds ownership: 31.06% → 46.99% (+16%)
4% more funds holding
Funds holding: 26 → 27 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
+$8.44M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$8.44M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
+$4.32M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$513K |
| 5 |
CC
Checkpoint Capital
San Francisco,
California
|
+$444K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
US Bancorp
Minneapolis,
Minnesota
|
-$156K |
| 2 |
WIA
Wetzel Investment Advisors
Indianapolis,
Indiana
|
-$3.68K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$1K |
| 4 |
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
|
-$167 |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$24 |
CDTX Hedge Fund Activity: Q3 2024 in Review
27 of the 6,977 institutional investors tracked by Wall St. Rank reported a position in Cidara Therapeutics (CDTX) for Q3 2024, worth a combined $35.6M — up 111% from $16.9M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new CDTX positions and 5 closed out — a net gain of 1 holder — while 9 added to existing stakes and 0 trimmed.
The largest buyer was Bain Capital Life Sciences Investors, opening a new position worth an estimated $8.44M. The largest seller was US Bancorp, exiting entirely with an estimated $156K sold.
- 27 institutional investors held Cidara Therapeutics (CDTX) as of Q3 2024, up from 26 in Q2 2024.
- Funds reported $35.6M of Cidara Therapeutics stock for Q3 2024, up 111% quarter-over-quarter.
- 6 funds opened new Cidara Therapeutics positions in Q3 2024 and 5 closed out, a net change of +1 holder.
- The largest Cidara Therapeutics buyer in Q3 2024 was Bain Capital Life Sciences Investors, an estimated $8.44M added.
- The largest Cidara Therapeutics seller in Q3 2024 was US Bancorp, an estimated $156K sold.
Based on aggregated 13F filings for Q3 2024.